CoChat
Sign Up
Cited by 161Nanoparticle-Based Drug DeliveryAdvanced Drug Delivery SystemsBarrier Structure and Function Studies

Theranostic applications of nanoparticles in neurodegenerative disorders

Open access
Ramanathan, Sahana, Archunan, Govindaraju, Sivakumar, Muthusamy, Tamil Selvan, Subramanian, Fred, A Lenin, Kumar, Sundramurthy, Gulyás, Balázs, Padmanabhan, Parasuraman·2018·International Journal of Nanomedicine
DOI 10.2147/ijn.s149022PMC PMC6154717
Open this paper in CoChat — free accountOpen PDF

Abstract

The preeminent treatments for neurodegenerative disease are often unavailable due to the poor accessibility of therapeutic drugs. Moreover, the blood-brain barrier (BBB) effectively blocks the transfer of cells, particles and large molecules, ie, drugs, across the brain. The most important challenge in the treatment of neurodegenerative diseases is the development of targeted drug delivery system. Theranostic strategies are known to combine therapeutic and diagnostic capabilities together. The aim of this review was to record the response to treatment and thereby improve drug safety. Nanotechnology offers a platform for designing and developing theranostic agents that can be used as an efficient nano-carrier system. This is achieved by the manipulation of some of the properties of nanoparticles (NPs), thereby enabling the attachment of suitable drugs onto their surface. The results provide revolutionary treatments by stimulation and thus interaction with targeted sites to promote physiological response with minimum side effects. This review is a brief discussion of the administration of drugs across the brain and the advantages of using NPs as an effective theranostic platform in the treatment of Alzheimer's, Parkinson's, epilepsy and Huntington's disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/ijn.s149022

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 89

  1. [2]Neuwelt EA Bauer B Fahlke C Engaging neuroscience to advance translational research in brain barrier biology Nat Rev Neurosci 2011 12 3 169 182 21331083 PMC3335275
  2. [3]Weksler BB Subileau EA Perrière N Blood-brain barrier-specific properties of a human adult brain endothelial cell line FASEB J 2005 19 13 1872 1874 16141364
  3. [4]Davson H Segal MB Physiology of the CSF and Blood-Brain Barriers Boca Raton CRC Press 1996 11
  4. [5]Bolognesi ML From imaging agents to theranostic drugs in Alzheimer’s disease Reference Module in Chemistry, Molecular Sciences and Chemical Engineering New York Elsevier 2017 74 106
  5. [6]Sikkandhar MG Nedumaran AM Ravichandar R Theranostic probes for targeting tumor microenvironment: an overview Int J Mol Sci 2017 18 5 E1036 28492519 PMC5454948
  6. [7]Sridhar S Mishra S Gulyás M Padmanabhan P Gulyás B An overview of multimodal neuroimaging using nanoprobes Int J Mol Sci 2017 18 2 311 PMC5343847 28157157
  7. [8]Moreno-Gonzalez I Soto C Misfolded protein aggregates: Mechanisms, structures and potential for disease transmission Semin Cell Dev Biol 2011 22 5 482 487 21571086 PMC3175247
  8. [9]Sweeney P Park H Baumann M Protein misfolding in neurodegenerative diseases: implications and strategies Transl Neurodegener 2017 6 1 6 28293421 PMC5348787
  9. [10]Begley DJ Kreuter J Do ultra-low frequency (ULF) magnetic fields affect the blood-brain barrier? Holick MF Jung EG Biologic Effects of Light 1998 Boston, MA Springer US 1999 297 301
  10. [11]Juillerat-Jeanneret L The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles? Drug Discov Today 2008 13 23–24 1099 1106 18848640
  11. [12]Begley DJ Brightman MW Structural and functional aspects of the blood-brain barrier Prog Drug Res 2003 61 39 78 14674608
  12. [13]Olivier J-C Drug transport to brain with targeted nanoparticles NeuroRx 2005 2 1 108 119 15717062 PMC539329
  13. [14]Gabathuler R Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases Neurobiol Dis 2010 37 1 48 57 19664710
  14. [16]Persidsky Y Ramirez SH Haorah J Kanmogne GD Blood-brain barrier: structural components and function under physiologic and pathologic conditions J Neuroimmune Pharmacol 2006 1 3 223 236 18040800
  15. [17]Singh R Lillard JW Nanoparticle-based targeted drug delivery Exp Mol Pathol 2009 86 3 215 223 19186176 PMC3249419
  16. [18]Choi HS Liu W Misra P Renal clearance of nanoparticles Nat Biotechnol 2007 25 10 1165 17891134 PMC2702539
  17. [19]Bhadra D Bhadra S Jain P Jain N Pegnology: a review of PEG-ylated systems Pharmazie 2002 57 1 5 29 11836932
  18. [20]Wilson B Samanta MK Santhi K Kumar KPS Paramakrishnan N Suresh B Poly (n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer’s disease Brain Res 2008 1200 159 168 18291351
  19. [22]Borm PJ Robbins D Haubold S The potential risks of nano-materials: a review carried out for ECETOC Part Fibre Toxicol 2006 3 11 16907977 PMC1584248
  20. [23]Roduner E Size matters: why nanomaterials are different Chem Soc Rev 2006 35 7 583 592 16791330
  21. [25]Janib SM Moses AS MacKay JA Imaging and drug delivery using theranostic nanoparticles Adv Drug Deliv Rev 2010 62 11 1052 1063 20709124 PMC3769170
  22. [26]Chen Z Small-molecule delivery by nanoparticles for anticancer therapy Trends Mol Med 2010 16 12 594 602 20846905 PMC3729441
  23. [27]Li W Luo R Lin X Remote modulation of neural activities via near-infrared triggered release of biomolecules Biomaterials 2015 65 76 85 26142778
  24. [28]Müller RH Jacobs C Kayser O Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future Adv Drug Deliv Rev 2001 47 1 3 19 11251242
  25. [29]Wilson B Samanta MK Santhi K Kumar KPS Paramakrishnan N Suresh B Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles Eur J Pharm Biopharm 2008 70 1 75 84 18472255
  26. [30]Kulkarni PV Roney CA Antich PP Bonte FJ Raghu AV Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer’s disease Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010 2 1 35 47 20049829
  27. [31]Wilson B Samanta MK Santhi K Kumar KPS Ramasamy M Suresh B Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine Nanomedicine 2010 6 1 744 750 19446656
  28. [32]Zhao X Li F Li Y Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer Biomaterials 2015 46 13 25 25678112
  29. [34]Zhao L Zhou Y Gao Y Bovine serum albumin nanoparticles for delivery of tacrolimus to reduce its kidney uptake and functional nephrotoxicity Int J Pharm 2015 483 1–2 180 187 25681723
  30. [35]Haller E Lindner W Lämmerhofer M Gold nanoparticle-antibody conjugates for specific extraction and subsequent analysis by liquid chromatography-tandem mass spectrometry of malondialdehyde-modified low density lipoprotein as biomarker for cardiovascular risk Anal Chim Acta 2015 857 53 63 25604820
  31. [36]Fu YC Fu TF Wang HJ Aspartic acid-based modified PLGA-PEG nanoparticles for bone targeting: in vitro and in vivo evaluation Acta Biomater 2014 10 11 4583 4596 25050775
  32. [37]Kumar GS Kulkarni A Khurana A Kaur J Tikoo K Selenium nanoparticles involve HSP-70 and SIRT1 in preventing the progression of type 1 diabetic nephropathy Chem Biol Interact 2014 223 125 133 25301743
  33. [38]Miguel L Noiray M Surpateanu G Iorga BI Ponchel G De & Poly (γ-benzyl-l-glutamate)-PEG-alendronate multivalent nanoparticles for bone targeting Int J Pharm 2014 460 1–2 73 82 24211357
  34. [39]Yilmaz A Rösch S Klingel K Magnetic resonance imaging (MRI) of inflamed myocardium using iron oxide nanoparticles in patients with acute myocardial infarction – preliminary results Int J Cardiol 2013 163 2 175 182 21689857
  35. [40]Badr G Al-Sadoon MK Rabah DM Therapeutic efficacy and molecular mechanisms of snake (Walterinnesia aegyptia) venom-loaded silica nanoparticles in the treatment of breast cancer- and prostate cancer-bearing experimental mouse models Free Radic Biol Med 2013 65 175 189 23811005
  36. [41]Gao Y Gu W Chen L Xu Z Li Y The role of daidzein-loaded sterically stabilized solid lipid nanoparticles in therapy for cardio-cerebrovascular diseases Biomaterials 2008 29 30 4129 4136 18667234
  37. [42]Kaur IP Bhandari R Bhandari S Kakkar V Potential of solid lipid nanoparticles in brain targeting J Control Release 2008 127 2 97 109 18313785
  38. [43]Faraji AH Wipf P Nanoparticles in cellular drug delivery Bioorg Med Chem 2009 17 8 2950 2962 19299149
  39. [44]Kreuter J Ramge P Petrov V Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles Pharm Res 2003 20 3 409 416 12669961
  40. [45]Volicer L Management of severe Alzheimer’s disease and end-of-life issues Clin Geriatr Med 2001 17 2 377 391 11375141
  41. [46]Forchetti CM Treating Patients With Moderate to Severe Alzheimer’s Disease: Implications of Recent Pharmacologic Studies Prim Care Companion J Clin Psychiatry 2005 7 4 155 161 16163398 PMC1192433
  42. [47]Selkoe DJ Schenk D Alzheimer’s disease: molecular understanding predicts amyloid-based therapeutics Annu Rev Pharmacol Toxicol 2003 43 1 545 584 12415125
  43. [48]Mahmoudi M Shokrgozar MA Multifunctional stable fluorescent magnetic nanoparticles Chem Commun 2012 48 33 3957 3959 22422277
  44. [49]Helzner EP Scarmeas N Cosentino S Tang MX Schupf N Stern Y Survival in Alzheimer disease: a multiethnic, population-based study of incident cases Neurology 2008 71 19 1489 1495 18981370 PMC2843528
  45. [50]Xie J Brayne C Matthews FE Medical Research Council Cognitive Function and Ageing Study Collaborators Survival times in people with dementia: analysis from population based cohort study with 14 year follow-up BMJ 2008 336 7638 258 262 18187696 PMC2223023
  46. [51]Allinson TM Parkin ET Turner AJ Hooper NM ADAMs family members as amyloid precursor protein alpha-secretases J Neurosci Res 2003 74 3 342 352 14598310
  47. [52]Dickson DW Crystal HA Bevona C Honer W Vincent I Davies P Correlations of synaptic and pathological markers with cognition of the elderly Neurobiol Aging 1995 16 3 285 298 7566338
  48. [53]Terry RD Masliah E Salmon DP Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment Ann Neurol 1991 30 4 572 580 1789684
  49. [54]Begley DJ Delivery of therapeutic agents to the central nervous system: the problems and the possibilities Pharmacol Ther 2004 104 1 29 45 15500907
  50. [55]Roney C Kulkarni P Arora V Targeted nanoparticles for drug delivery through the blood–brain barrier for Alzheimer’s disease J Control Release 2005 108 2 193 214 16246446
  51. [56]Tanifum EA Dasgupta I Srivastava M Intravenous delivery of targeted liposomes to amyloid-β pathology in APP/PSEN1 transgenic mice PLoS One 2012 7 10 e48515 23119043 PMC3485335
  52. [57]Cui Z Lockman PR Atwood CS Novel d-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer’s and other CNS diseases Eur J Pharm Biopharm 2005 59 2 263 272 15661498
  53. [58]Agyare EK Curran GL Ramakrishnan M Yu CC Poduslo JF Kandimalla KK Development of a smart nano-vehicle to target cerebrovascular amyloid deposits and brain parenchymal plaques observed in Alzheimer’s disease and cerebral amyloid angiopathy Pharm Res 2008 25 11 2674 2684 18712585 PMC3766361
  54. [60]Zhang C Chen J Feng C Intranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer’s disease Int J Pharm 2014 461 1–2 192 202 24300213
  55. [61]Zhang C Wan X Zheng X Dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer’s disease mice Biomaterials 2014 35 1 456 465 24099709
  56. [62]Li Y Xu D Ho SL Li HW Yang R Wong MS A theranostic agent for in vivo near-infrared imaging of β-amyloid species and inhibition of β-amyloid aggregation Biomaterials 2016 94 84 92 27107167
  57. [63]Fisher RS Ho J Potential new methods for antiepileptic drug delivery CNS Drugs 2002 16 9 579 593 12153331
  58. [64]De Tiège X Laufs H Boyd SG EEG-fMRI in children with pharmacoresistant focal epilepsy Epilepsia 2007 48 2 385 389 17295635
  59. [65]Moody WJ Futamachi KJ Prince DA Extracellular potassium activity during epileptogenesis Exp Neurol 1974 42 2 248 263 4824976
  60. [66]Rutecki PA Lebeda FJ Johnston D Epileptiform activity induced by changes in extracellular potassium in hippocampus J Neurophysiol 1985 54 5 1363 1374 2416891
  61. [67]Huang WC Hu SH Liu KH Chen SY Liu DM A flexible drug delivery chip for the magnetically-controlled release of anti-epileptic drugs J Control Release 2009 139 3 221 228 19607866
  62. [68]Couvreur P Vauthier C Nanotechnology: intelligent design to treat complex disease Pharm Res 2006 23 7 1417 1450 16779701
  63. [70]Ito F Fujimori H Makino K Incorporation of water-soluble drugs in PLGA microspheres Colloids Surf B Biointerfaces 2007 54 2 173 178 17137764
  64. [71]Friese A Seiller E Quack G Lorenz B Kreuter J Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly (butylcyanoacrylate) nanoparticles as a parenteral controlled release system Eur J Pharm Biopharm 2000 49 2 103 109 10704892
  65. [72]Ying X Wang Y Liang J Angiopep-conjugated electro-responsive hydrogel nanoparticles: therapeutic potential for epilepsy Angew Chem Int Ed Engl 2014 53 46 12436 12440 25044856
  66. [73]Hsiao MH Larsson M Larsson A Design and characterization of a novel amphiphilic chitosan nanocapsule-based thermo-gelling biogel with sustained in vivo release of the hydrophilic anti-epilepsy drug ethosuximide J Control Release 2012 161 3 942 948 22652548
  67. [74]Fu T Kong Q Sheng H Gao L Value of functionalized superpara-magnetic iron oxide nanoparticles in the diagnosis and treatment of acute temporal lobe epilepsy on MRI Neural Plast 2016 2016 2412958 26925269 PMC4748095
  68. [75]Singh N Pillay V Choonara YE Advances in the treatment of Parkinson’s disease Prog Neurobiol 2007 81 1 29 44 17258379
  69. [76]Johnston TH Fox SH Brotchie JM Advances in the delivery of treatments for Parkinson’s disease Expert Opin Drug Deliv 2005 2 6 1059 1073 16296809
  70. [77]Katzenschlager R Hughes A Evans A Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson’s disease: a prospective study using single-dose challenges Mov Disord 2005 20 2 151 157 15390035
  71. [78]Nyholm D Nilsson Remahl AI Dizdar N Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease Neurology 2005 64 2 216 223 15668416
  72. [79]Bennett JP Piercey MF Pramipexole – a new dopamine agonist for the treatment of Parkinson’s disease J Neurol Sci 1999 163 1 25 31 10223406
  73. [80]Patil RR Yu J Banerjee SR Probing in vivo trafficking of polymer/DNA micellar nanoparticles using SPECT/CT imaging Mol Ther 2011 19 9 1626 1635 21750533 PMC3182352
  74. [81]Obeso JA Rodriguez-Oroz MC Goetz CG Missing pieces in the Parkinson’s disease puzzle Nat Med 2010 16 6 653 661 20495568
  75. [82]Mena MA García de Yébenes J Glial cells as players in parkinsonism: the “good,” the “bad,” and the “mysterious” glia Neuroscientist 2008 14 6 544 560 19029058
  76. [83]Orr CF Rowe DB Halliday GM An inflammatory review of Parkinson’s disease Prog Neurobiol 2002 68 5 325 340 12531233
  77. [84]Fiandaca MS Forsayeth JR Dickinson PJ Bankiewicz KS Image-guided convection-enhanced delivery platform in the treatment of neurological diseases Neurotherapeutics 2008 5 1 123 127 18164491 PMC2719019
  78. [85]Neuwelt EA Mechanisms of disease: the blood-brain barrier Neurosurgery 2004 54 1 131 132 14683550
  79. [86]Klejbor I Stachowiak EK Bharali DJ ORMOSIL nanoparticles as a non-viral gene delivery vector for modeling polyglutamine induced brain pathology J Neurosci Methods 2007 165 2 230 243 17655935
  80. [87]Yurek DM Flectcher AM Kowalczyk TH Padegimas L Cooper MJ Compacted DNA nanoparticle gene transfer of GDNF to the rat striatum enhances the survival of grafted fetal dopamine neurons Cell Transplant 2009 18 10–11 1183 1196 19650971 PMC3031110
  81. [88]Wen Z Yan Z Hu K Odorranalectin-conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson’s disease following intranasal administration J Control Release 2011 151 2 131 138 21362449
  82. [89]Hu K Shi Y Jiang W Han J Huang S Jiang X Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson’s disease Int J Pharm 2011 415 1–2 273 283 21651967
  83. [90]Morrison PJ Accurate prevalence and uptake of testing for Huntington’s disease Lancet Neurol 2010 9 12 1147 21087736
  84. [91]Pringsheim T Wiltshire K Day L Dykeman J Steeves T Jette N The incidence and prevalence of Huntington’s disease: a systematic review and meta-analysis Mov Disord 2012 27 9 1083 1091 22692795
  85. [92]Wexler NS Lorimer J Porter J U.S.-Venezuela Collaborative Research Project Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington’s disease age of onset Proc Natl Acad Sci U S A 2004 101 10 3498 3503 14993615 PMC373491
  86. [93]Zuccato C Cattaneo E Huntington’s Disease Lewin G Carter B Neurotrophic Factors Handbook of Experimental Pharmacology 220 Berlin, Heidelberg Springer 2014
  87. [94]Ross CA Tabrizi SJ Huntington’s disease: from molecular pathogenesis to clinical treatment Lancet Neurol 2011 10 1 83 98 21163446
  88. [96]Sandhir R Yadav A Mehrotra A Sunkaria A Singh A Sharma S Curcumin nanoparticles attenuate neurochemical and neurobehavioral deficits in experimental model of Huntington’s disease Neuromolecular Med 2014 16 1 106 118 24008671
  89. [97]Bhatt R Singh D Prakash A Mishra N Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington’s disease Drug Deliv 2015 22 7 931 939 24512295 PMC11132712

Cited by

Sorted by citations

Authors
Ramanathan, S., Archunan, G., Sivakumar, M., Tamil Selvan, S., Fred, A. L., Kumar, S., Gulyás, B., & Padmanabhan, P.
Affiliations
  • Nanyang Technological University (SG)
  • Bharathidasan University (IN)
  • Anna University, Chennai (IN)
Corresponding author
  • Gulyás, Balázs
  • Padmanabhan, Parasuraman
ORCID
Venue
International Journal of Nanomedicine
Publisher
Informa UK Limited
Published
2018-09
Volume
Volume 13
Pages
5561-5576
ISSN
  • 1176-9114 (ISSN-L)
  • 1178-2013
DOI
10.2147/ijn.s149022
PMC
PMC6154717
OpenAlex
W2890838015
Cited by
161
References
1
Citations by year
2026: 14 · 2025: 20 · 2024: 24 · 2023: 15 · 2022: 24 · 2021: 30 · 2020: 25 · 2019: 9
FWCI
1.06
Type
journal article
Language
en
Open access
Licence
Locations
  • International Journal of Nanomedicine (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
  • DR-NTU (Nanyang Technological University) (submittedVersion, cc-by-nc)
Funders
  • Nanyang Technological University
  • University Grants Commission
  • Lee Kong Chian School of Medicine, Nanyang Technological University
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
Keywords
theranostics, nanoparticles, neurodegenerative diseases, blood-brain barrier, targeted drug delivery, nanocarriers, Alzheimer's disease, Parkinson's disease, epilepsy, Huntington's disease
MeSH terms
Theranostic Nanomedicine, Animals, Blood-Brain Barrier, Humans, Drug Delivery Systems, Neurodegenerative Diseases, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review